Dr. Feldman performs PFO closures, and teaches the technique worldwide. He has extensive experience in valvuloplasty, has built a leading program for aortic and mitral valvuloplasty with NorthShore University HealthSystem. Currently, several clinical trials and programs are underway to advance this area of interventional cardiology. Please click on a link below to find the specific criteria for each of these studies.

PFO Closure (stroke/migraine)

ESCAPE
The ESCAPE migraine trial is a randomized clinical trial that will evaluate PFO closure in patients with refractory migraine headache

PFO Access (non-research)
Percutaneous Device Closure of Patent Foramen Ovale to lower the overall risk of recurrent stroke

Balloon Mitral Valvuloplasty (non-research)
Percutaneous commissurotomy for rheumatic mitral stenosis

Aortic Valvuloplasty for Critical, Symptomatic Aortic Valve Stenosis in high risk surgical or non-operative candidates (non-research)

Percutaneous Valve Device Procedures

Everest II (Evalve) 
Everest II is a randomized clinical trial designed to compare the percutaneous mitral repair system to surgical mitral repair or replacement, for degenerative or functional mitral regurgitation.  Study participants are randomized 3:2 (2 out of 3 times to the MitraClip repair procedure and 1 out of 3 times to open heart surgery).

PARTNER (Placement of Aortic Transcatheter Valves)
Percutaenous stent mounted pericardial tissue valve for severe aortic stenosis in patients who are considered a high risk or non-operative candidates for conventional aortic valve replacement surgery.

Other

WATCHMAN
Randomized comparison of percutaenous left atrial appendage occlusion vs. Coumadin® in patients who have atrial fibrillation and are taking   Coumadin®. The purpose of this study is to offer an alternative to the need for long-term anticoagulant therapy.

FREEDOM
Randomized comparison of PCI with drug eluting stents vs CABG in diabetics with multivessel CAD. This study will help determine the optimal treatment for diabetic patients with multivessel coronary artery disease. Patients will be randomly assigned to receive either surgery or stenting. This trial will not address left main stenosis, which was the subject of the recently completed SYNTAX trial.

× Alternate Text